Fundraising Fox
Seattle · Growth · 91 people tracked
Also known as Frazier Healthcare · Frazier Management, L.L.C.
Find your way into Frazier Healthcare Partners
Sign up to see every warm intro you have to Frazier Healthcare Partners
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Frazier Healthcare Partners team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Frazier Healthcare Partners applies a multi-decade, healthcare-specialized investment approach through its Growth Buyout strategy, partnering with profitable and growing companies across the healthcare sector. The firm pairs high-conviction investment themes with proven operating executives, sourced through its Executive in Residence program and extensive healthcare network. Beyond capital, Frazier provides in-house functional resources to help portfolio companies build human capital, strengthen operational infrastructure, and navigate rapid growth, often supporting buy-and-build strategies. The Buyout group has scaled significantly since 1995 and raised over $11 billion of capital for private funds and co-investment opportunities from institutional limited partners globally.
Source: firm website, verified Oct 13, 2026.
Team · 91 people
from the firm's website & curated & public directoriesGeneral Partner who joined Frazier in 2003, serving on boards including Leiters and Matrix Medical Network and leading the Growth Buyout team's debt capital markets. Previously worked at Summit Partners. Holds BS and MS degrees from Stanford.
General Partner on the Growth Buyout team who joined in 2019, representing Frazier on boards including United Derm Partners and RevSpring. Previously a Principal at Norwest Equity Partners. Holds an MBA from Harvard Business School.
Joined Frazier in 2024 as a General Partner on the Structured Solutions team. Previously spent over five years at SVB Capital / WestRiver Group and held roles at Comerica Bank. Holds a BA in Accounting from the University of Puget Sound.
General Partner on the Growth Buyout team who leads Frazier's New York office, joining in 2012. Serves on boards including AirLife and CSafe. Previously an Analyst at RBC Capital Markets. Holds a BS in Economics from Wharton.
General Partner on the Growth Buyout team who joined in 2016, serving on boards including CareTria and Vatica Health. Previously spent five years at Kohlberg & Company and worked at JPMorgan. Holds a BS from Brigham Young University.
Joined Frazier in 1991 and has served on the firm's Management and Investment Committees, leading the Buyout team since 1995. He has served on boards of numerous portfolio companies including CHG Healthcare and Solis Mammography. Holds an MBA from NYU Stern and a BA from the University of Pennsylvania.
Joined Frazier in April 2023 as a talent leader with a track record of scaling organizations. Previously on the management team at Bridgewater Associates for nearly two decades as it grew to 1500 people and $150 billion AUM.
Joined Frazier in February 2024 as a Partner on the Structured Solutions team. Previously spent five years at SVB Capital / WestRiver Group and eight years at Comerica Bank. Holds a BA and MBA from Washington State University.
Partner on the Growth Buyout team who joined in 2016 and serves on boards including Tri-Imaging Solutions. Previously worked at The Edgewater Funds and CIVC Partners. Holds a BS in Biomedical Engineering and an MBA from Northwestern.
Joined Frazier in 2016, serving on boards including Altruix and Vatica Health. Previously an Analyst at Harris Williams & Co. Holds a BS in Business Administration from UNC Chapel Hill.
Brent Fierro is a growth equity investor at FTV Capital focused on financial technology and services, where he has worked for over 12 years since joining in 2013. He previously was an investment banking analyst in the financial institutions group at Houlihan Lokey and began his career at the New York Stock Exchange in strategy and data analytics.
Shalom Nahum joined Gemini in 2007 as Senior Controller and became CFO in 2014, focusing on fund management, valuation, and performance analysis. He previously worked as Controller at IBC and Senior Accountant at KPMG, and holds a BA in Business Administration and an MBA in Finance.
Dan Estes is a General Partner at Frazier Life Sciences, which he joined in 2011, where he invests in development-stage and commercial-stage pharmaceutical companies. He has co-founded and helped launch several portfolio companies and previously worked as a management consultant in McKinsey & Company's healthcare practice, advising pharmaceutical and biotech firms on R&D and business development strategy. He holds a Ph.D. in Biomedical Engineering from the University of Michigan and a B.S. in Electrical Engineering from Stanford University.
Gordon Empey is Chief Operating Officer, General Counsel, and a Partner at Frazier Life Sciences, which he joined in 2017, overseeing the firm's legal, operations, investor relations, compliance, HR, IT, and administrative functions. He has more than 25 years of experience advising venture capital investors and life sciences companies, previously serving as a partner at Cooley LLP and as EVP and General Counsel at Radiant Research, and earlier as General Counsel of the Frazier-sponsored SPAC that merged to form NewAmsterdam Pharma. He holds a J.D. from UC Berkeley (Boalt Hall) and a B.A. in History from Colgate University, and earlier served as an officer in the U.S. Navy Judge Advocate General Corps.
Jamie is a General Partner and Portfolio Manager at Frazier Life Sciences, which he joined in 2016, investing in private and public biotechnology companies. He co-leads Frazier's public equity investment strategy and serves as co-Portfolio Manager of the Frazier Life Sciences Public Fund alongside Albert Cha. Before Frazier, he was a management consultant at the Boston Consulting Group within its Healthcare Practice, and he holds an M.D. from the University of Southern California and a B.A. from Middlebury College.
Patrick Heron co-leads Frazier's Life Sciences team and is a Managing Partner and co-founder of that team, having joined the firm in 1999 and opened its Palo Alto office in 2003. He invests across therapeutics, from early-stage drug development to commercial-stage pharmaceutical companies. Before Frazier, he helped build McKinsey & Company's West Coast biotechnology consulting practice, and he holds an M.B.A. from Harvard Business School and a B.A. from the University of North Carolina at Chapel Hill.
Joined Frazier in July 2023 as a Senior Associate and was promoted to Vice President in August 2025. Involved with portfolio companies including CareTria and RevSpring. Previously a Senior Manager at Zymergen and Associate Director at UBS. Holds an MBA from Wharton.
Joined Frazier in 2019 and serves on the board of RevSpring. Previously worked at McKinsey, co-founded a startup, and held roles at Credit Suisse and Morgan Stanley. Holds an MBA and MPH from UC Berkeley.
Joined Frazier in February 2024 as a Vice President on the Structured Solutions team. Previously a Vice President at SVB Capital and Associate at Silicon Valley Bank focusing on venture debt. Holds a BA from Brandeis University.
Joined Frazier in July 2022 as a Senior Associate and was promoted to Vice President in 2024. Involved with portfolio companies including Adare Pharma Solutions. Previously a Senior Associate at the Abu Dhabi Investment Authority. Holds an MBA from Wharton.
Joined Frazier in October 2022 as an Associate, rising to Vice President. Involved with portfolio companies including AirLife and EPTAM Precision. Previously an Associate at Carlyle and Analyst at J.P. Morgan. Holds a BS in Business from NYU.
Joined Frazier in 2016 as an Associate, later spending time at portfolio company Leiters before rejoining the investment team in 2019. Sits on boards including CareTria and LUX Infusion. Holds a BA in Economics from Middlebury College.
Joined Frazier in August 2022 with over 20 years of M&A and management consulting experience, leading integration and value maximization efforts across the portfolio. Previously a Senior Director at A&M's PE practice, at EY-Parthenon, and six years at McKinsey.
Joined Frazier in July 2025 as a Vice President on the Growth Buyout team. Previously spent four years at New Mountain Capital and worked at WindRose Health Investors and Jefferies. Holds an MBA from Wharton.
Laura Gleason Moore is Director of Operations at Berggruen Holdings, where she oversees operational strategy, processes, and performance across multiple sectors and regions in coordination with the CFO and other senior leaders. She joined the company more than seven years ago as Administrative Director before advancing to her current role, working on structuring, financing, compliance, investment projects, business development, and communications. Her earlier career included real estate positions at Colony Capital, GPI Companies, and Joseph Cohen Real Estate, and she studied English and Business at USC.
Maria Fardis joined Frazier Life Sciences as a Venture Partner in 2021 and has more than 20 years of scientific and management experience across public and private companies. She currently serves as CEO of Lassen Therapeutics and previously held leadership roles including President and CEO of Iovance Biotherapeutics, COO of Acerta Pharma, and senior positions at Pharmacyclics and Gilead Sciences. She holds a Ph.D. in Organic Chemistry from UC Berkeley, a B.S. in chemistry from the University of Illinois, Urbana-Champaign, and an M.B.A. from Golden Gate University.
Joined Frazier in April 2023 with over 20 years of IT experience in architecture, delivery, and cost optimization. Previously Senior Director of Data Engineering at Mercury Healthcare/WebMD and Director at Optum. Holds a BS and BBA from Minnesota Duluth and MBA from Carlson.
Joined Frazier in August 2024 as an Associate on the Growth Buyout team. Previously an Analyst at TD in Vancouver. Holds a Bachelor of Commerce from the University of British Columbia.
Joined Frazier in 2016 and became a Center of Excellence Partner, later serving as COO of the Center of Excellence team focused on human capital and ESG. Previously a Partner at Green Peak and expert at McKinsey. A former U.S. Army Aviation Officer. Holds a Masters from Columbia and BS from West Point.
Center of Excellence Partner for technology and innovation since 2015, with extensive experience in IT applications and infrastructure. Previously Director of Applications for TridentUSA. Holds a BA from the University of Washington.
Joined Frazier in April 2025 as a Center of Excellence Partner for finance and operations, bringing over two decades of experience. Serves on the board of Knipper Health. Previously CFO at IMG Academy and CPS. Holds a BBA from Franklin University and MBA from Vanderbilt.
Joined Frazier in January 2023, rising to Partner by 2026, supporting portfolio companies in finance, supply chain, and analytics. Previously spent nearly 10 years at Providence health system. Holds a BA from Middlebury and MBA from University of Michigan Ross.
Joined Frazier in April 2026 as a Center of Excellence Principal for Data & AI on the Growth Buyout team. Previously SVP and CIO at MultiCare Health System. Holds an MS from Brown and an MBA from Pacific Lutheran University.
Joined Frazier in July 2024 as an Associate on the Growth Buyout team. Previously an investment banking analyst at Deloitte Corporate Finance. Holds a BS and BA from UNC Chapel Hill.
Joined Frazier in August 2023 as an Associate and was promoted to Senior Associate in 2025. Previously an Investment Banking Analyst at Deutsche Bank. Holds a BA in Economics from Northwestern.
Re-joined Frazier as an Executive in Residence focused on home health, hospice and related areas. Previously co-founder and CFO of Abode Healthcare, a Frazier portfolio company acquired by BrightSpring Healthcare, and earlier worked at Trident Capital, Spectrum Equity Investors, and Alex. Brown.
Joined Frazier in July 2025 as an Associate on the Growth Buyout team. Previously an investment banker at TD Cowen. Holds a BS in Biological Sciences from Cornell.
Joined Frazier in 2021 with over 20 years of experience in enterprise risk management, regulatory compliance, and information security. Previously CISO of a public multinational company and led IT compliance at a home-healthcare firm. Prior roles at KPMG and Protiviti.
Joined Frazier in October 2024 as a Senior Associate on the Growth Buyout team. Previously a Senior Associate at Grant Avenue Capital and Associate at Piper Sandler. Holds a BBA from the University of Michigan.
Joined Frazier in July 2025 as an Associate on the Growth Buyout team. Previously an Investment Banking Associate at Deutsche Bank. Holds a BA in Mathematics and Economics from Hamilton College.
Joined Frazier in July 2024 as an Associate on the Growth Buyout team. Previously an investment banker at Solomon Partners and Fenchurch Advisory Partners. Holds a BA in Classics from the University of Bristol.
Joined Frazier in February 2022 with over 20 years of experience in corporate FP&A and data analytics. Previously Director of Finance at Fiserv and Director of FP&A at Healthcare Solutions. Holds a BBA in Accounting from Georgia State University.
Joined Frazier in January 2023 as a Center of Excellence Vice President for legal, with over 10 years of legal experience. Previously VP, Senior Corporate Counsel at AmTrust and an Associate at Goodwin Procter. Holds a BA from Cornell and JD from Fordham.
Joined Frazier in November 2021 with over 10 years of experience in data science and analytics focused on healthcare. Previously Director of Data Science at Healthgrades and roles at Verizon and Capital BlueCross. Holds a BS from Bucknell and MS from Northwestern.
Joined Frazier's Growth Buyout team in 2005 as a Center of Excellence Partner for finance and operations. Serves on the board of AirLife and various public boards. Previously CFO of First Health. A CPA who began at Peat Marwick. Holds a BA from Luther College.
Joined Frazier in July 2025 as an Associate on the Growth Buyout team. Previously an Investment Banking Analyst at Bank of America. Holds a BBA in Finance from Notre Dame.
Joined Frazier in August 2021 as a Center of Excellence Partner for Data & AI on the Growth Buyout team. Previously SVP and GM of Data, Analytics, and Insights at Clarivate and 18 years at Decision Resources Group. Holds a BASc from the University of Toronto.
Joined Frazier in January 2026 as a Center of Excellence Principal for sales excellence with over 20 years in healthcare and life sciences. Previously VP and Head of the Cell & Gene Service Line at Cencora and senior roles at CVS Health. Holds a BS from the University of Arizona.
Joined Frazier in September 2025 as a Senior Associate on the Growth Buyout team. Previously a Senior Associate at The Vistria Group and Analyst at William Blair. Holds a BA in Economics from the University of Chicago.
Joined Frazier in July 2026 as Director of Deal Origination on the Center of Excellence team. Previously a business development professional at Lincoln International and at PitchBook Data. Holds a BA in Communication from North Carolina State University.
Joined Frazier in July 2023 as an Associate and was promoted to Senior Associate in 2025. Previously an Investment Banking Analyst at TD Cowen. Holds a BA in Economics from Claremont McKenna College.
Joined Frazier in May 2024 focused on women's health and wellness. Former CEO of Thinx, which she scaled to a $130M+ brand and sold to Kimberly Clark, with prior executive roles at eBay, Fab.com, Thomson Reuters, Dow Jones, Yahoo, and Disney.
Joined Frazier in August 2021, involved with portfolio companies including Konovo and Altruix. Previously an Associate at Sheridan Capital Partners and Analyst at William Blair. Holds a BA in Economics from Indiana University.
Joined Frazier in August 2022 as a Center of Excellence Partner for M&A with over 20 years of consulting and transaction experience. Previously a Senior Director at A&M and roles at EY-Parthenon and McKinsey. Holds an MBA from Cornell.
Joined Frazier in June 2026 focused on clinical services investments. Former CEO of Kindeva Drug Delivery and SCA Pharmaceuticals, with a career spanning pharmaceutical contract development and manufacturing (CDMOs).
Joined Frazier in July 2025 as an Associate on the Growth Buyout team. Previously an Investment Banking Analyst at Piper Sandler. Holds a BA in Economics from UC San Diego.
Joined Frazier in April 2023, promoted to Center of Excellence Principal for commercial strategy and marketing in 2025. Previously VP of Commercial Strategy at Cerberus and Director of Strategy at Publicis Groupe. Holds a BA from UPenn and MBA from NYU Stern.
Joined Frazier in February 2025 as Director of Data & AI with over 15 years in data science and healthcare analytics. Previously Senior Director of Data Science at Eversana. Holds an MS from McMaster University and a BS from the University of Khartoum.
Joined Frazier in May 2021 as a member of the Center of Excellence Technology and Innovation team with over 16 years in healthcare. Previously Director of IT Operations at SOCTelemed. Holds a BS from George Mason University and PMP certification.
Joined Frazier in 2014 as General Counsel and Center of Excellence Partner for legal and operations. Previously General Counsel of Aptalis Pharmaceuticals and senior executive at APP Pharmaceuticals. Holds a JD from Santa Clara and an LLM from Boston University.
Joined Frazier in May 2024 as a Center of Excellence Partner for Data & AI on the Growth Buyout team. Previously SVP of AI Products and Platforms at Optum and founder of OptumLabs' Center for Applied Data Science. Holds a BS in Computer Science from Trinity College.
Joined Frazier in January 2025 as a Center of Excellence Principal for technology and innovation with over 20 years in tech. Previously VP in portfolio operations at Brookfield Asset Management and Cerberus. Holds a BS from Amravati University and MBA from IIM Lucknow.
Joined Frazier in July 2024 as a Center of Excellence VP of Corporate Development, promoted to Principal in 2026. Founded M&A advisory firm Black Eagle Advisors and previously led corporate development at MiX Telematics. Holds a BS from USC and MBA from Harvard.
Joined Frazier in June 2026 focused on healthcare information technology. Former CEO of HealthEdge, which he grew to $400M+ revenue through two exits, and previously a healthcare venture capital partner at the Psilos Group.
Clarissa Berman is a Principal at Frazier Healthcare Partners. Her experience spans private and public equities, business and corporate strategy, and start-ups.
Investment consultant supporting investment banks and management firms across traditional and alternative investments including hedge funds, fund of funds, private equity, VC, and wealth management.
Chris Peetz is Chief Executive Officer and co-founder of Mirum Pharmaceuticals. He brings experience in finance, corporate development, marketing, and executive leadership within the biopharmaceutical industry.
Gordon McMurray joined Frazier Life Sciences as an Entrepreneur-in-Residence in March 2020 and has over 18 years of experience in drug discovery and development. He previously co-founded and served as Chief Scientific Officer at Outpost Medicine, and earlier held senior R&D roles at Pfizer across neuroscience, pain, sensory disorders, and urology, as well as a lectureship and lab head position in pharmacology at Oxford University. He earned a B.Sc. and Ph.D. from Queen's University Belfast.
Ian W. Mills is an Entrepreneur-in-Residence at Frazier Life Sciences, having joined in March 2020, with a background as a pharmaceutical development executive. He previously served as Chief Medical Officer at Outpost Medicine and Head of Clinical Development at Mitsubishi Tanabe Pharma Europe, and spent over 15 years at Pfizer in clinical and development leadership roles. He holds an MA in Natural Sciences from Cambridge University and a medical degree and medical doctorate from Oxford University.
Investor, operator, and board director with 25+ years scaling consumer and healthcare businesses; former CEO and board member of Thinx, with prior leadership roles at eBay, Yahoo, Thomson Reuters, Dow Jones, Fab.com, and Disney.
Angel Martin is a Vice President at Frazier Life Sciences, which she joined in 2021 to evaluate investment opportunities in the life sciences sector. She previously worked as an Investment Fellow with Vertex Ventures Healthcare and held roles as Director of Research and Venture Grants at Emerson Collective, Health and Research Director of the Friedreich Ataxia Research Alliance. She holds a Ph.D. in Pharmacology and Cancer Biology from Duke University and a B.A. from the University of Michigan, Ann Arbor.
Joe Cabral is a Partner at Frazier Life Sciences, which he joined in 2021, working on the firm's private investment and company creation strategies. Before that, he worked in venture creation at Flagship Pioneering and was a founding team member at Generate:Biomedicines in protein engineering and strategy roles, and earlier was an early employee at Moderna focused on molecular biology and informatics. He holds an MBA from the University of Michigan's Ross School of Business, and an M.S. in Genomics and a B.S. in Biology from the University of Connecticut.
Founder mafia
9 people who came through Frazier Healthcare Partners went on to found or lead other companies.
What they invest in
from 73 of 101 portfolio companiesHealthtech ×51Biotech ×36Medical Devices ×24Digital Health ×23SaaS ×10Advanced Manufacturing ×9AI & Machine Learning ×6Enterprise Software ×6
HQs:United States×47Canada×1Germany×1United Kingdom×1
Investments · 101 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 52024 · 32023 · 12022 · 32021 · 52020 · 52019 · 32018 · 12017 · 12016 · 22014 · 132 dated
BrightSpring Health Services operates complementary home and community-based health services for complex populations requiring specialized or chronic care, including home health, hospice, senior care, and pharmacy management across all 50 U.S. states.
Digital HealthHealthtechWellness & Fitness
Jennifer Yowler(President, PharMerica)Mike McMaude(President, Home Health and Hospice Services)Jim Mattingly(Executive Vice President and Chief Financial Officer)inLisa Nalley(Chief of Staff and Senior Vice President, Human Resources)inJon Rousseau(Chairman, President, and Chief Executive Officer)inBob Barnes(President, Community Living)
Co-investorsEpsilon Health Investors
Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.
AI & Machine LearningBiotechSouth San Francisco, US
Charles Homcy(Director)Jason Coloma(Chief Executive Officer)in
Co-investorsAndreessen HorowitzARCH Venture PartnersForesite CapitalFrazier Life SciencesGV (Google Ventures)Hercules Capital, Inc.+9 more
Mirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases.
BiotechHealthtechSan Diego, US
Chris Peetz(Co-founder & Chief Executive Officer)inEric Bjerkholt(Executive Officer)inPeter Radovich(Executive Officer)in
BoardPatrick Heron(Director)inMichael Grey(Director)Timothy Walbert(Director)
Co-investorsChiesi VenturesFrazier Life SciencesLongitude CapitalMESA VERDE VENTURE PARTNERSNew Enterprise Associates (NEA)Pappas Capital+4 more
Passage Bio is a biotechnology company developing treatments for central nervous system (CNS) diseases, with a focus on neurodegenerative conditions.
BiotechHealthtechPhiladelphia, US
William Chou(Chief Executive Officer)Tadataka Yamada(Executive Officer, Director, Promoter)Stephen Squinto(Executive Officer, Director)in
BoardPatrick Heron(Director)inCarl Gordon(Director)inThomas Street Address 1 Woiwode(Director)
Co-investorsFrazier Life SciencesAccess BiotechnologyLilly Asia VenturesNew Leaf Venture PartnersOrbiMedSphera Funds Management+2 more
Vatica Health develops software solutions for primary care physicians, health plans, and providers to improve the Medicare Annual Wellness Visit and risk adjustment processes.
Digital HealthEnterprise SoftwareHealthtechMedical DevicesSaaS
Steve Zuckerman(Co-founder)inAverel Snyder(Co-founder)inKeith Anderson(Chief Executive Officer)in
Co-investorsGreat Hill PartnersOptum Ventures
Accuity provides software solutions to hospitals for managing clinical documentation standards, regulatory compliance, and healthcare revenue cycle optimization.
AI & Machine LearningDigital HealthHealthtechSaaS
Adare Pharma Solutions is a CDMO (contract development and manufacturing organization) and pharma services provider serving the biopharma industry with manufacturing, research and development, and patient support capabilities.
Advanced ManufacturingBiotechHealthtechMedical Devices
Tom Sellig(Chief Executive Officer)inJason Arcediano(Chief Commercial Officer)inDavid Durkin(Chief Financial Officer)inRussell Lindenfeldar(Chief Legal Officer)inLuisa Rodriguez(Chief Human Resources Officer)inNaresh Sethi(Chief Information Officer)in
Agiliti provides medical equipment management, rental, and clinical engineering services to hospitals and health systems, helping them keep devices available and maintained while controlling costs and meeting compliance requirements.
Digital HealthHealthtechLogistics & Supply ChainMedical Devices
Tom Leonard(Chief Executive Officer)Matthew McCabe(Executive Vice President and Chief Financial Officer)Bettyann Bird(Executive Vice President and Chief Strategy Officer)Bob Creviston(Executive Vice President and Chief Human Resources Officer)Lee Neumann(Executive Vice President and General Counsel)Matt Neale(Senior Vice President of IT and Chief Information Officer)
AirLife manufactures airway management medical devices, including endotracheal tubes and pharyngeal airways, used to maintain or restore safe airways for oxygenation and ventilation.
Advanced ManufacturingHealthtechMedical DevicesGrand Rapids, US
Co-investorsArieal Southeast Angel Partners
Alesta Therapeutics develops therapies for rare diseases, with research focused on genetic diseases and oncology.
BiotechHealthtech
Ilan Ganot(CEO)inBenit Maru(CMO)Matthias Van Woensel(CSO)in
Co-investorsDroia VenturesFrazier Life SciencesNovartis Venture FundRV Invest GmbHMPM BioImpactRTW Investments L.P.+1 more
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(Founder)Kuo-Shyan Lin(Founder)David Perrin(Founder)
Co-investorsAndreessen HorowitzAscenta CapitalDelos CapitalFrazier Life SciencesGeneral CatalystLightspeed Venture Partners+9 more
.png)
Alteon Health is a physician-owned and physician-led acute care medical group that partners with hospitals and health systems to provide hospitalist medicine, post-acute care, and clinical staffing.
Digital HealthHealthtech
Co-investorsNew Mountain Capital
Altruix operates local, independent pharmacies in the mid-Atlantic region, offering person-centered pharmacy services that specialize in behavioral health, intellectual and developmental disabilities, and substance use disorder.
Digital HealthHealthtechMental Health
Randy Hyun(Chief Executive Officer)in
Biopharmaceutical company discovering and developing novel biologics, protein, and peptide therapeutics.
BiotechSouth San Francisco, US
Trisha Millican(Director)James Topper(Director)Otello Stampacchia(Director)David Hirsch(Director)Volker Schellenberger(Executive Officer)James Brush(Director)
Co-investorsBain Capital Life SciencesFrazier Life SciencesLongitude CapitalViking GlobalBlackRockCasdin Capital+6 more
Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.
BiotechDeep TechDigital HealthMedical DevicesSan Diego, US
Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inANDRÉS BRATT-LEAL, Ph.D.(Co-Founder; Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)inDAMIEN MCDEVITT, Ph.D.(President and Chief Executive Officer)
Co-investorsARCH Venture PartnersLifeforce CapitalOrbiMedDomain AssociatesEDB InvestmentsSection 32+10 more
Bluejay is a biotechnology company focused on therapeutic development.
BiotechSan Mateo, US
Keting Chu(Founder, Chief Executive Officer and Chairman of the Board)inDajun Yang(Director)Nancy Hong(Director)inAlon Lazarus(Director)William J. Rutter(Director)Ting Jia(Director)
Co-investorsFrazier Life SciencesRA CapitalRiverVest Venture PartnersWellington ManagementHBM Healthcare InvestmentsNovo Holdings+2 more
Medicare Advantage and Part D prescription drug plans; based in Baltimore, MD.
Co-investorsNew Enterprise Associates (NEA)
Calistoga Pharmaceuticals is a pharmaceutical company.
BiotechHealthtechSeattle, US
Co-investorsFrazier Life SciencesAlta PartnersAmgen Ventures
Caravel engineers proteins into scalable industrial "protein machines" for applications including critical minerals recovery, carbon capture, and industrial processes.
BiotechClimate TechDeep Tech
Trevor Nicks(Founder & CEO)inEmily Bowman(CSO)inMichał Jastrzębski(CTO)inAgneya Bhushan(CINO)in
Co-investors2048 VenturesPioneerPortland Seed FundThe Venture Collective
Caravel Autism Health provides evaluation, diagnosis, and data-driven therapy programs for children with autism, supported by their proprietary PathTap™ outcomes platform for clinical progress tracking and analysis.
Digital HealthHealthtechMedical DevicesMental Health
Prior Firm Investment shown for illustrative purposes; not a Whistler fund investment.
Co-investorsLeonard GreenNew Enterprise Associates (NEA)Whistler Capital Partners
Cirius Therapeutics is a clinical-stage pharmaceutical company developing therapies for patients with chronic metabolic diseases driven by insulin resistance, including Type 2 Diabetes and obesity.
BiotechDigital HealthGrand Rapids, US
Jerry Callahan(Executive Officer)Brian Farmer(Executive Officer)inRobert Baltera(Executive Officer, Director)Howard Dittrich(Executive Officer)
BoardMichael Jandernoa(Director)Mark Olesnavage(Executive Officer)
Co-investorsFrazier Life SciencesNovo Holdings
CPS Solutions provides pharmacy management services to hospitals and health systems, including specialty pharmacy, 24/7 telepharmacy support (remote order entry and verification, transitions of care), 340B compliance, rehabilitation, and materials management.
Digital HealthEnterprise SoftwareHealthtech
Co-investorsAscension Ventures
Provides healthcare services to underserved populations in state hospitals and detention settings; based in Nashville, TN.
CSafe develops temperature-controlled shipping solutions for the pharmaceutical and life sciences cold chain, including active and passive air cargo containers, parcel shippers, and cryogenic dewars for cell and gene therapies.
Advanced ManufacturingBiotechHealthtechIoTLogistics & Supply ChainMonroe, US
Patrick Schafer(Chief Executive Officer)Scott Lathrop(Chief Financial Officer)inNiall Prendiville(Chief (Engineering/Operations))inMicki Turner(Chief Human Resources Officer)Sofia Pokatilova(Chief Legal / General Counsel)in
Co-investorsBCI
Effective School Solutions provides guidance and resources to school districts on securing and sustaining funding for mental and behavioral health services.
Digital HealthEdTechGovTechHealthtechMental Health
Dr. Norris(Chief Executive Officer)inLisa Ciappi(Chief Clinical Officer)inJerry(Chief Clinical Officer)
Co-investorsHavencrest Capital Management
Elevate Patient Financial Solutions provides revenue cycle management services for healthcare providers, including eligibility, complex claims, third party liability, workers' compensation, extended business office, and patient care scheduling.
FintechHealthtechSaaS
Michael Shea(Chairman & Chief Executive Officer)Frank Stellato(Chief Financial Officer)Nicole Guido(Chief Growth Officer)Emily Fisher(Division President & COO, Patient Outreach)Justin Myers(Division President & COO, Complex Claims)Jack Tindal(Chief People Officer)
EPTAM provides precision machining, plastics, and molding manufacturing services for regulated industries including medical and aerospace sectors.
Advanced ManufacturingBiotechHardwareHealthtechMedical DevicesBoston, US
Bill Flaherty(President & Chief Commercial Officer)inJudson Samuels(Executive Officer)Mark Jrolf(Executive Officer)
A pharmaceutical company that markets a portfolio of drug products across various dosage forms, with labeling and packaging following FDA requirements.
Advanced ManufacturingBiotechHealthtechLogistics & Supply Chain
Rick Ryan(Executive Director and Founder, WSI)Benjamin Hall(Chief Executive Officer)inDavid Arnold(President/Chief Operating Officer)inSonia De La Rosa(Chief Commercial Officer, Corporate Development and Strategy)in
Co-investorsFulcrum Equity PartnersNew Enterprise Associates (NEA)Frazier
Nexoplex Bio develops immunotherapies that target tumor cells through recognition of HLA-peptide complexes using multi-specific antibodies, addressing tumor types including lung, gastric, esophageal, head and neck, cervical cancers, and lung squamous cell carcinoma.
BiotechDeep TechHealthtechSan Carlos, US
Wayne(CEO)Rachel(VP of Operations)
Co-investorsBay City CapitalGV (Google Ventures)LAVLilly Asia VenturesAlexandriaThe Column Group+1 more
XOMA Royalty is a biotech royalty aggregator that acquires the economic rights to future milestone and royalty payments tied to partnered pre-commercial clinical candidates, providing sellers with non-dilutive, non-recourse funding.
BiotechFintech
Co-investorsCatalys PacificFrazier Life SciencesLightspeed Venture PartnersRA CapitalSamsara BioCapital
Hillstar Bio develops precision immunotherapies for autoimmune diseases, using antibody engineering to selectively deplete pathogenic immune cells while sparing healthy ones.
BiotechHealthtech
Co-investorsDroia VenturesFrazier Life SciencesLifeArc Ventures
HOPCo brings together executives from musculoskeletal medicine, hospital and health system management, insurance, and healthcare IT to manage and coordinate care and alternative payment models.
Digital HealthHealthtechMedical DevicesPhoenix, US
David J. Jacofsky(Founder, Chairman and Chief Executive Officer)inWael Barsoum(President & Chief Transformation Officer)inLeAnne Stewart(Chief Financial Officer)Jason Scalise(Chief Value Officer)inPeter J. Slate(Chief Corporate Development Officer)inChris Martinez(Global Chief Information Officer)in
Co-investorsPrinceton
OLG Machinery, founded in 2008, trades new and certified used industrial spare parts and machinery, serving U.S. companies operating across North and South America with a focus on Mexico.
Advanced ManufacturingB2B MarketplacesLogistics & Supply Chain
Co-investorsOxford Investment Opportunity Network (OION)Ally Bridge GroupAltium CapitalAmgen VenturesDroia VenturesNovo Holdings+2 more
Hummingbird Bioscience is a precision biotherapeutics company developing a pipeline of novel targeted therapies for cancer, using proprietary drug discovery technologies and platforms.
AI & Machine LearningBiotechDeep TechHealthtech
Piers Ingram(Chief Executive Officer, Co-Founder, Executive Director)inJerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)inKonrad Paszkiewicz(Chief Technology Officer)inKwek Kon Yew(Chief Medical Officer)Dipti Thakkar(Chief Operating Officer)in
Co-investorsAltium CapitalClavystBioDecheng CapitalDroia VenturesFrazier Life SciencesKiwoom Investment+6 more
A pharmaceutical company that develops medicines and vaccines, with research pipelines and clinical trials aimed at new treatments.
BiotechHealthtech
Co-investorsFrazier Life SciencesHighlight CapitalMRL Ventures FundXeraya CapitalAmgen VenturesBlackRock+5 more
Inipharm is a clinical-stage biopharmaceutical company developing small-molecule inhibitors targeting HSD17B13 to treat severe fibrotic liver diseases, including MASH and other conditions with established genetic validation.
BiotechHealthtechMedical Devices
Brian Farmer(Co-Founder, Chief Executive Officer)inHeather Hsu, PhD(Co-Founder, Chief Scientific Officer)Michael Gallatin, PhD(Co-Founder, SAB Chair)Chuhan Chung(Chief Medical Officer)in
Co-investors5AM VenturesFrazier Life SciencesWu Capital
Iolyx is a pharmaceutical company focused on developing treatments for ocular conditions.
BiotechMedical Devices
Elizabeth Jeffords(CEO & President)inErin Newman(Chief Development Officer)inShannon Dahl(Chief Scientific Officer)inBryan Boyle(Chief Legal & Administrative Officer)in
Co-investorsAlumni VenturesFrazier Life Sciences
Iterum provides appliance management infrastructure for institutional landlords, combining procurement, maintenance, and data analytics to optimize operational efficiency and reduce costs.
Data & InfrastructureEnterprise SoftwarePropTechSaaSLondon, GB
Jon Holden(CEO)inFelix Dahlke(CTO)
Co-investorsClearance Venture PartnersSustainable VenturesCanaan PartnersNew Leaf Venture PartnersSofinnova Ventures
Knipper provides multi-modal pharmaceutical fulfillment and dispensing services, including patient access solutions, pharmacy fulfillment, samples management, and third-party logistics for pharma companies.
Digital HealthHealthtechLogistics & Supply Chain
Co-investorsFrazier Life Sciences
Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.
Biotech
David King(Co-Founder & CSO)inMaria Fardis(CEO)inCadmus C. Rich(Chief Medical Officer)inElaine Stracker(General Counsel)in
Co-investorsAlta PartnersCatalio Capital Management, LPDC Investment PartnersFrazier Life SciencesLongitude CapitalLongwood Fund+2 more
Leiters Health is an FDA-registered 503B outsourcing facility that produces sterile compounded preparations for hospitals, surgery centers, and ophthalmic use.
BiotechHealthtechMedical DevicesDenver, US
Co-investorsCorewell Health VenturesDementia Discovery FundEscalate Capital PartnersH.I.G. CapitalH.I.G. HealthBridge PartnersIntermountain Health+4 more
LUX Infusion operates infusion centers and pharmacies that administer specialty intravenous and subcutaneous medications for patients with autoimmune disorders, neurological conditions, immune deficiencies, chronic infections, and other complex conditions.
Digital HealthHealthtechMedical Devices
Matrix Medical Network is an independent provider of comprehensive in-home health assessments serving people across the United States.
Digital HealthHealthtechMedical Devices
Marcia Naveh, MD, FACP, CMD(Founder)in
Co-investorsAdams Street Partners
MatrixCare provides digital software tools designed for post-acute care settings, including home-based and long-term care facilities, to manage patient intake, medical records, pharmacy, reimbursement, and compliance.
Digital HealthEnterprise SoftwareHealthtechSaaS
Tim Smokoff(General Manager, MatrixCare)in
Co-investorsOMERS Private Equity Inc.
MBX Biosciences is a clinical-stage biopharmaceutical company developing peptide therapeutics for endocrine and metabolic diseases.
BiotechHealthtechCarmel, US
Richard DiMarchi(Founder)Peter Kent Hawryluk(Executive Officer, Director)Timothy Knickerbocker(Executive Officer, Director)inSteve Hoerter(Chairman & Chief Executive Officer)inSalomon Azoulay(Chief Medical Officer)inKaren Basbaum(Chief Business Officer)in
Co-investorsFrazier Life SciencesNorwest Venture PartnersIU VenturesNew Enterprise Associates (NEA)OrbiMedWellington Management
Proofpoint provides cybersecurity and compliance software that protects organizations' people, data, cloud environments, and email from advanced cyber threats.
AI & Machine LearningCybersecurityEnterprise SoftwareSaaS
Ashan Willy(CEO)Sumit Dhawan(Chief Executive Officer)Rémi Thomas(Chief Financial Officer)Kim Sullivan(Chief People Officer)Mayank Choudhary(EVP and GM, Information Protection, Cloud Security & Compliance Products Group)Tom Corn(EVP and GM, Threat Protection Group)
Co-investorsCrane Venture PartnersDag VenturesElevate VenturesGamutGlynn Capital ManagementGranite Hill+11 more
PCI is a contract development and manufacturing organization (CDMO) that supports pharmaceutical clients from early-stage drug development through commercialization, including sterile drug manufacturing.
Advanced ManufacturingBiotechHealthtech
PCI is a contract development and manufacturing organization (CDMO) that supports pharmaceutical and biotech clients from early-stage development through commercialization, including sterile drug manufacturing.
Advanced ManufacturingBiotechHealthtech
Pentec Health is a national provider of clinical nutrition and specialty care services, integrating pharmacy services with clinical expertise for patients with complex conditions including dialysis, wound care, metabolic disorders, and oncology needs.
Digital HealthHealthtechMedical Devices
Joe Cosgrovein
Co-investorsWellspring
This page is a distribution, marketing, and reseller partner directory for PRWeb, an online press release distribution service.
Marketing TechMedia & EntertainmentSaaS
Co-investorsAdvance Venture PartnersAngel Physicians FundAvestria VenturesAviv Venture CapitalBIGR VenturesBlue Venture Funds+15 more
PharmiWeb.com was an online career and jobs community for the pharmaceutical industry, connecting professionals with opportunities from entry-level to VP positions.
HealthtechHR Tech
Press Publications operates a local news outlet covering communities in the east metro area of Minnesota, including White Bear Lake, Shoreview, Arden Hills, and Mahtomedi.
Media & Entertainment
Psych Congress runs in-person psychiatry conferences and educational events focused on practical psychopharmacology and clinical treatment strategies.
EdTechHealthtechMental Health
BiotechMenlo Park, US
Brett Ewald(Executive Officer)inUmesh Gangadharmath(Executive Officer)inIstvan Molnar(Executive Officer)inYunfei Zhu(Executive Officer)Ana Kusnetzow(Executive Officer)inScott Struthers(Director)
Co-investorsDCVC (Data Collective)Frazier Life Sciences5AM VenturesDCVC BioWestlake Village BioPartners
RevSpring provides patient and member engagement solutions for healthcare providers and payers, combining behavioral data, financial insights, and multi-channel (digital and print) communications to guide patients from provider search through final payment.
AI & Machine LearningDigital HealthHealthtech
Brandon Spring(Chief Commercial Officer & Kyruus GM)
Co-investorsAntares CapitalBeringeaNew Enterprise Associates (NEA)
Sidewinder Therapeutics is a biotechnology company focused on oncology drug discovery and development, working on next-generation cancer treatments.
BiotechHealthtechMedical DevicesSan Diego, US
Eric Murphy(Chief Executive Officer, Co-Founder, & Director)in
Co-investorsAstellas Venture Management LLCDCVC (Data Collective)DCVC BioFrazier Life SciencesLongwood FundNovartis Venture Fund+2 more
Solis Mammography operates specialized breast imaging centers offering screening and diagnostic mammograms using 3D mammography and SmartCurve compression technology, along with AI-assisted early cancer detection.
FemTechHealthtechMedical Devices
Co-investorsEpsilon Health InvestorsTowerBrook
Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Jeffrey Bluestone(Founder)inJeff Bluestone, PhD(Founder and Scientific Advisor; co-founder and former President and CEO)Qizhi Tang, PhD(Founder and Scientific Advisor)Fred Ramsdell, PhD(Founder and Scientific Advisor)Alexander Rudensky, PhD(Founder and Scientific Advisor)Stephen Dilly, MBBS, PhD(President and Chief Executive Officer)
Co-investors8VCARCH Venture PartnersFrazier Life SciencesGV (Google Ventures)JDRF T1D FundLAV+6 more
Sudo Biosciences develops small molecule therapeutics for neurological and immune-mediated inflammatory conditions.
BiotechHealthtechMedical DevicesMenlo Park, US
Jim Bristol(Director)Daniel Estes(Director)inScott Byrd(Executive Officer, Director)in
Co-investorsFrazier Life SciencesMonograph Capital PartnersPICUS CAPITALSanofi VenturesSV Health InvestorsDementia Discovery Fund+3 more
Transform magazine is a quarterly publication covering brand strategy, rebranding, and brand development across sectors globally.
Marketing TechMedia & Entertainment
Tri-Imaging sells, leases, repairs, and sources parts for medical imaging equipment, and operates an apprenticeship program for training professionals in medical imaging services.
HardwareHealthtechMedical DevicesNashville, US
Eric Wright(Founder)in
TridentCare provides clinical services to elderly and post-acute patients through a combination of technology and clinical workforce.
Digital HealthHealthtechLogistics & Supply ChainMedical Devices
David Velezin
Tubulis develops antibody-drug conjugates (ADCs) for cancer treatment, using proprietary conjugation platform technologies to create tumor-targeting therapeutics.
BiotechDeep TechMedical DevicesPlanegg-Martinsried, DE
Dominik Schumacher(Co-founder & CEO)inJonas Helma-Smets(Co-founder & Chief Scientific Officer)Christian Hackenberger(Scientific Co-founder)
Co-investorsAndera PartnersBioMedPartnersEQT Life SciencesNexTech VenturesAscenta CapitalBayern Kapital+8 more
U.S.
Digital HealthHealthtechMedical Devices
Co-investorsHealth Velocity CapitalKaiser Permanente VenturesLeonard GreenNew Enterprise Associates (NEA)Revelstoke Capital PartnersSummit Partners+1 more
United Digestive is a provider of gastroenterology and digestive healthcare services, operating through partner physician practices that offer diagnostic and in-office treatment services.
Digital HealthHealthtechAtlanta, US
Evan Wildstein(President)Whitney Hanson(Vice President and Secretary)Mark Gilreath(Chief Executive Officer)inRobert A. Cucuel, Jr.(Director)Neal C. Patel(Director)H. Lynn Massingale(Director)
United Derm Partners provides patient-centered services to dermatology practices across the United States.
Digital HealthHealthtechMedical DevicesSaaSBrentwood, US
Vuru was an online tool that analyzed public companies' financial statements into simplified stock reports and portfolio-tracking for retail investors.
Co-investorsBackbone Angels
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Abode HealthcareAccuityAccuity Delivery SystemsAdareBE BiopharmaBeckersascCallio TherapeuticsCareTriaCPS SolutionsCSafeDSI RenalEIS investmentElevate Patient Financial SolutionsImago BioSciences, Inc.Laboratory Supply CompanyLabscoMedPointeMerganser BiotechNorthfield MedicalOcteta TherapeuticsOutpost MedicinePriority SolutionsRecida TherapeuticsSanReno TherapeuticsSolis MammographyTailwind Capital Acquires Abode HealthcareTrident USA Health ServicesUnited Derm
Exits · 24
4 IPOs · 20 acquisitions · showing 23BrightSpring Louisville, KYNASDAQ: BTSGMaze TherapeuticsNASDAQ: MAZEMirum PharmaceuticalsNASDAQ: MIRMPassage BioNASDAQ: PASGAbode Healthcareacq. by Tailwind CapitalAlteon Healthacq. by US Acute Care SolutionsBluejaytxacq. by Mirum PharmaceuticalsBravo Healthacq. by HealthSpringGolden State Medical Supplyacq. by Court Square Capital PartnersHilleVaxacq. by XOMA RoyaltyImagoacq. by MerckLaboratory Supply Companyacq. by McKessonMedPointeacq. by MedaNorthfield Medicalacq. by AgilitiParataacq. by BDPentec Healthacq. by Norwest Equity PartnersPentec Health Celebrates 35th Anniversaryacq. by Wellspring Capital ManagementPriority Solutionsacq. by Thermo Fisher ScientificSolis Mammographyacq. by Madison Dearborn PartnersTrident USA Health Servicesacq. by Formation CapitalTubulis GmbHacq. by Gilead SciencesUnited Digestiveacq. by Kohlberg & CompanyVuruacq. by Wave Accounting (Wave Financial/Wave HQ)
Portfolio news
latest coverage across their companies
Passage Bio · stocktitan.net · Aug 10, 2026
Vatica Health · resources.workable.com · Jun 26, 2026
Caravel Bio · finance.yahoo.com · May 12, 2026
Cirius Therapeutics · prnewswire.com · Apr 28, 2026
Aspen Neuroscience · prnewswire.com · Nov 20, 2025
Fund performance · per public LP disclosures · 7
as of Mar 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Frazier Life Sciences Public Overage FundLPs: Empire State Development – New York Ventures | 2022 | — | — | 1.28x | 0.17x |
| Frazier Life Sciences Public Fund, LPLPs: Empire State Development – New York Ventures | 2021 | — | — | 1.47x | 0.37x |
| Frazier Healthcare Ventures V, L.P.LPs: California State Teachers' Retirement System | 2005 | — | 14.7% | 2.28x | 2.28x |
| Frazier Technology Ventures II, L.P.LPs: Public Employee Retirement System of Idaho | 2004 | — | 14.4% | 4.46x | 4.46x |
| Frazier Healthcare IV, L.P.LPs: Washington State Investment Board, John D. and Catherine T. MacArthur Foundation | 2001 | — | 0.7% | 1.00x | 1.04x |
| Frazier Healthcare III, L.P.LPs: Washington State Investment Board | 1998 | — | -11.1% | 0.50x | 0.47x |
| Frazier Healthcare II, L.P.LPs: Washington State Investment Board | 1996 | — | 6.9% | 1.50x | 1.46x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- How many investments has Frazier Healthcare Partners made?
- Frazier Healthcare Partners has 101 tracked investments, 24 of which have exited, including 7 dated in the last 24 months.
- What stage does Frazier Healthcare Partners invest at?
- Frazier Healthcare Partners invests at the Growth stage.
- What is Frazier Healthcare Partners's typical check size?
- Frazier Healthcare Partners typically writes checks of $50M – $400M.
- What sectors does Frazier Healthcare Partners focus on?
- Frazier Healthcare Partners focuses on Biotech, Digital Health, FemTech, Healthtech, Medical Devices, Wellness & Fitness.
- Where is Frazier Healthcare Partners located?
- Frazier Healthcare Partners is headquartered in Seattle, US.
- Who does Frazier Healthcare Partners co-invest with?
- Frazier Healthcare Partners most often shares deals with New Enterprise Associates (NEA), Frazier Life Sciences, Kaiser Permanente Ventures, among 75 tracked co-investors.
Media · Podcasts & interviews
featuring the team13 Brian Morfitt2017 HCFC: Frazier Healthcare Partners | Brian Morfitt
UCI Merage School · Brian Morfitt
Co-investors · 28
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Norwest is a venture capital and growth equity investment firm that has backed over 700 companies across technology, consumer, and healthcare over its 65-year history.
Novartis Venture Fund is the corporate venture arm investing in life science companies, backing innovative drugs and treatments across various stages of growth.
Nextech Invest is a Zurich-based investor backing emerging biotechnology companies worldwide, focused on advancing precision medicine and transformative cancer therapies.
Samsara BioCapital is a life-sciences investment firm backing companies developing transformative therapeutics for patients.
Alta Partners is a venture capital firm focused on the healthcare and life sciences sector, backing entrepreneurs building companies across biotechnology, therapeutics, and healthcare innovation.
General Catalyst is a global venture capital and investment firm backing founders across stages and industries, with a notable focus on AI, healthcare transformation, defense, and space.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Versant Ventures operates in-house Discovery Engines staffed by multidisciplinary scientists in dedicated laboratory facilities to help launch new biotechnology companies alongside academic founders.
5AM Ventures is a life science venture capital firm founded in 2002 that funds and builds next-generation life sciences companies, focusing on biopharmaceuticals, drug delivery technologies, and life science instruments.
▶16 more co-investors
Omega FundsRiverVest Venture PartnersNew Leaf Venture PartnersCanaan PartnersVenrockEQT Life SciencesDeerfield Management CompanySanofi VenturesMPM BioImpactDomain AssociatesThird Rock VenturesSofinnova VenturesAndera PartnersWestlake Village BioPartnersAsset Management VenturesAisling Capital
Firms observed investing alongside Frazier Healthcare Partners, from public investor directories. Shared companies are the overlap with Frazier Healthcare Partners's recorded portfolio.
Similar investors
Suncoast Ventures is a venture capital firm focused on healthcare, backing companies that solve costly, overlooked problems in the sector and helping them scale through relationships, networks, and operational systems.
Everywhere Ventures is an early-stage venture firm that writes pre-seed checks and is backed by a community of founder and operator LPs.
LongeVC is a venture capital firm backing early-stage founders in biotech and longevity, aiming to bring breakthrough science and treatments to market.
Foreground Capital is a venture capital firm dedicated to investing in the future of women's health, building on its predecessor track record at RH Capital.
Avestria Ventures is a San Francisco Bay Area venture capital firm that backs early-stage women's health companies and female-led life science ventures.